Preclinical findings on the potential of intranasal neuropeptide Y for treating hyperarousal features of PTSD

Ann N Y Acad Sci. 2019 Nov;1455(1):149-159. doi: 10.1111/nyas.14172. Epub 2019 Jun 27.

Abstract

Acoustic startle response (ASR) assesses hyperarousal, a core symptom of posttraumatic stress disorder (PTSD). Intranasal neuropeptide Y (NPY) administration was shown to prevent hyperarousal in single prolonged stress (SPS) rodent PTSD model. However, it is unclear how ASR itself alters responses to stress. Rats (A-S-A) were exposed to acoustic startle (AS) 1 day before SPS (ASR1) and 2 weeks afterward (ASR2). Other groups were exposed in parallel to either AS (A-A) or SPS or neither. SPS enhanced ASR2. In relevant brain areas, mRNA levels were determined by qRT-PCR. In mediobasal hypothalamus, AS or SPS each increased CRH mRNA levels without an additive effect. Exposure to AS appeared to dampen some responses to SPS. The SPS-triggered reduction of GR and FKBP5 gene expression was not observed in A-S-A group. In locus coeruleus, SPS increased CRHR1 and reduced Y2R mRNAs, but not in A-S-A group. In both regions, AS altered NPY receptor gene expression, which may mediate dampening responses to SPS. In second experiment, intranasal NPY administered 2 weeks after SPS reversed hyperarousal symptoms for at least 7 days. This study reveals important effects of AS on the NPY system and demonstrates that intranasal NPY elicits long-lasting reversal of traumatic stress-triggered hyperarousal.

Keywords: CRH; PTSD; acoustic startle; hyperarousal; intranasal NPY; locus coeruleus.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Administration, Intranasal
  • Animals
  • Arousal / drug effects*
  • Male
  • Nasal Cavity / metabolism*
  • Neuropeptide Y / administration & dosage
  • Neuropeptide Y / pharmacology
  • Neuropeptide Y / therapeutic use*
  • Rats
  • Rats, Sprague-Dawley
  • Stress Disorders, Post-Traumatic / drug therapy*

Substances

  • Neuropeptide Y